Health Care & Life Sciences » Pharmaceuticals | Bio-Path Holdings Inc.

Bio-Path Holdings Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
3,551.80
13,858.80
8,854.50
9,375.00
5,965.00
1,004
Other Current Assets
115.50
255.20
738.50
1,278.00
1,470.00
925
Total Current Assets
3,667.30
14,114.00
9,593.00
10,653.00
7,435.00
1,929
Net Property, Plant & Equipment
-
113.10
72.00
614.00
654.00
406
Intangible Assets
1,411.50
1,250.90
1,090.30
929.00
769.00
-
Total Assets
5,078.80
15,478.00
10,755.30
12,196.00
8,858.00
2,335
Accounts Payable
76.10
-
-
69.00
52.00
Other Current Liabilities
218.80
562.00
937.40
981.00
739.00
Total Current Liabilities
294.90
562.00
937.40
1,050.00
791.00
Other Liabilities
-
-
-
2,906.00
-
Total Liabilities
294.90
562.00
937.40
3,956.00
791.00
Common Equity (Total)
4,783.90
14,916.00
9,817.80
8,240.00
8,067.00
Total Shareholders' Equity
4,783.90
14,916.00
9,817.80
8,240.00
8,067.00
Total Equity
4,783.90
14,916.00
9,817.80
8,240.00
8,067.00
Liabilities & Shareholders' Equity
5,078.80
15,478.00
10,755.30
12,196.00
8,858.00

About Bio-Path Holdings

View Profile
Address
4710 Bellaire Boulevard
Bellaire Texas 77401
United States
Employees -
Website http://www.biopathholdings.com
Updated 07/08/2019
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P.